Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Accumulated Depreciation & AmortizationCost of RevenueDepreciation & Amortization (IS)Depreciation ExpenseEBIATLeasesLong-Term Debt IssuancesMachine, Furnitures, Fixtures & OtherOther Gross PP&E AdjustmentsProperty, Plant & Equipment (Gross)Receivables - NetShares RepurchasedShort-Term Debt repayments
Ratios

Ani Pharmaceuticals (ANIP) EBIAT (2016 - 2025)

Ani Pharmaceuticals' EBIAT history spans 15 years, with the latest figure at $27.5 million for Q4 2025.

  • For Q4 2025, EBIAT rose 367.86% year-over-year to $27.5 million; the TTM value through Dec 2025 reached $78.3 million, up 522.94%, while the annual FY2025 figure was $78.3 million, 522.94% up from the prior year.
  • EBIAT for Q4 2025 was $27.5 million at Ani Pharmaceuticals, up from $26.6 million in the prior quarter.
  • Across five years, EBIAT topped out at $27.5 million in Q4 2025 and bottomed at -$24.2 million in Q3 2024.
  • The 5-year median for EBIAT is -$1.1 million (2021), against an average of -$596750.0.
  • The largest annual shift saw EBIAT tumbled 23506.98% in 2022 before it skyrocketed 1165.25% in 2024.
  • A 5-year view of EBIAT shows it stood at -$24.1 million in 2021, then surged by 82.42% to -$4.2 million in 2022, then surged by 127.22% to $1.2 million in 2023, then crashed by 989.7% to -$10.3 million in 2024, then surged by 367.86% to $27.5 million in 2025.
  • Per Business Quant, the three most recent readings for ANIP's EBIAT are $27.5 million (Q4 2025), $26.6 million (Q3 2025), and $8.5 million (Q2 2025).